Top

Published in:

01-01-2021 | Hepatocellular Carcinoma | Original Article

MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma

Authors: Long Yang, Zheyue Yuan, Yamin Zhang, Zilin Cui, Yang Li, Jiancun Hou, Xiaolong Liu, Zirong Liu, Rui Shi, Qing Tian, Jian Wang, Lianjiang Wang

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2021

Abstract

Background

The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has been widely used as a new and reliable preclinical research model capable of predicting the sensitivities of anti-tumor drugs.

Methods

Twenty-eight patients with HCC were selected to use the MiniPDX model to screen the most sensitive anti-tumor drugs from five groups of drug regimens for preventive treatment after partial hepatectomy, and another 42 patients with HCC were selected to be treated with Sorafenib during the same period as the control group. The tumor-free survival rate and overall survival rate were analyzed and compared between these two groups. The relationship between drug sensitivity and biomarkers related to HCC was also analyzed.

Results

Kaplan–Meier survival curve analysis showed that the tumor-free survival (DFS) of patients in the MiniPDX group was significantly longer than that in the control group (median DFS: 25.8 months vs. 18.2 months, P = 0.022, HR 2.19, 95% CI 1.17–4.12). The overall survival (OS) of the patients in the MiniPDX group was also longer than that in the control group (median OS: 29.4 months vs. 23.8 months, P = 0.039, HR 2.37, 95% CI 1.12–5.00). The longest follow-up period was 36 months. The relationship analyzed between the efficacy of the five drugs (Regorafenib, Regorafenib, Lenvatinib, Gemcitabine, 5-FU + Oxaliplatin) and AFP, Ki-67, VEGFR, FGFR, P53, and Nrf2 showed different correlations.

Conclusion

The use of the MiniPDX model to select drugs to guide anti-tumor treatment after partial hepatectomy could effectively prolong the survival of patients with HCC.

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: Cancer J Clin 68(6):394–424

Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma [J]. Gastroenterology 156(2):477-491 e471PubMed

Hernandez MC, Bergquist JR, Leiting JL et al (2019) Patient-derived xenografts can be reliably generated from patient clinical biopsy specimens [J]. J Gastrointest Surg: Off J Soc Surg Aliment Tract 23(4):818–824

Malaney P, Nicosia SV, Dave V (2014) One mouse, one patient paradigm: new avatars of personalized cancer therapy [J]. Cancer Lett 344(1):1–12PubMed

Tentler JJ, Tan AC, Weekes CD et al (2012) Patient-derived tumour xenografts as models for oncology drug development [J]. Nat Rev Clin Oncol 9(6):338–350PubMedPubMedCentral

Huynh H, Ong R, Soo KC (2012) Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma [J]. Angiogenesis 15(1):59–70PubMed

Zhang F, Wang W, Long Y et al (2018) Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response [J]. Cancer Commun 38(1):60

Zhan M, Yang RM, Wang H et al (2018) Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients [J]. Cancer Commun 38(1):48

Cwinn M, Molinari M (2016) Regional variations in treatment modalities for hepatocellular carcinoma in Canada [J]. Hpb 18:e196–e197

10.

Raza A, Sood GK (2014) Hepatocellular carcinoma review: current treatment, and evidence-based medicine [J]. World J Gastroenterol 20(15):4115–4127PubMedPubMedCentral

11.

Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma [J]. Hepatology 48(4):1312–1327PubMedPubMedCentral

12.

Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the sharp trial [J]. Expert Rev Anticancer Ther 9(6):739–745PubMed

13.

Khandelwal G, Girotti MR, Smowton C et al (2017) Next-generation sequencing analysis and algorithms for pdx and cdx models [J]. Mol Cancer Res: MCR 15(8):1012–1016PubMed

14.

Koga Y, Ochiai A (2019) Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors [J]. Cells 8(5):418PubMedCentral

15.

Zhao P, Chen H, Wen D et al (2018) Personalized treatment based on mini patient-derived xenografts and wes/rna sequencing in a patient with metastatic duodenal adenocarcinoma [J]. Cancer Commun 38(1):54

16.

Cheng A-L, Finn RS, Qin S et al (2017) Phase iii trial of lenvatinib (len) vs sorafenib (sor) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uhcc) [J]. J Clin Oncol 35(15_suppl):4001–4001

17.

Llovet J, Cheng A, Qin S et al (2019) 6519 efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (hcc): collective results from the phase III sorafenib HCC assessment randomized protocol (sharp) and Asia-Pacific (AP) trials [J]. Eur J Cancer Suppl 7(2):367

18.

Llovet JM (2008) Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med 359(23):2498 (author reply 2498–2499)

19.

Ikeda M, Mitsunaga S, Ohno I et al (2015) Systemic chemotherapy for advanced hepatocellular carcinoma: Past, present, and future [J]. Diseases 3(4):360–381PubMedPubMedCentral

20.

Kudo M, Trevisani F, Abou-Alfa GK et al (2016) Hepatocellular carcinoma: therapeutic guidelines and medical treatment [J]. Liver cancer 6(1):16–26PubMedPubMedCentral

21.

Qin S, Cheng Y, Liang J et al (2014) Efficacy and safety of the folfox4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the each study [J]. Oncologist 19(11):1169–1178PubMedPubMedCentral

22.

Ikeda M, Morizane C, Ueno M et al (2018) Chemotherapy for hepatocellular carcinoma: current status and future perspectives [J]. Jpn J Clin Oncol 48(2):103–114PubMed

23.

Raghunath A, Sundarraj K, Arfuso F et al (2018) Dysregulation of nrf2 in hepatocellular carcinoma: role in cancer progression and chemoresistance [J]. Cancers 10(12):481PubMedCentral

24.

He C, Li L, Guan X et al (2017) Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy [J]. Chemotherapy 62(1):43–53PubMed

Title: MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma
Authors: Long Yang
Zheyue Yuan
Yamin Zhang
Zilin Cui
Yang Li
Jiancun Hou
Xiaolong Liu
Zirong Liu
Rui Shi
Qing Tian
Jian Wang
Lianjiang Wang
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Lenvatinib
Regorafenib
Sorafenib
Cytostatic Therapy
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2021
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-020-04182-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Artemisinin-type drugs for the treatment of hematological malignancies

Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)

Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin

Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer